A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76739 | Bococizumab | 1407495-02-6 | 98% |
|
Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprot... | ||||
T76735 | Mupadolimab | 2451856-97-4 | 98% |
Mupadolimab
|
Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells. | ||||
T76727 | Teprotumumab | 1036734-93-6 | 98% |
Teprotumumab
|
Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. T... | ||||
T76726 | Zagotenemab | 2019133-28-7 | 98% |
Zagotenemab
|
Zagotenemab is a humanized antibody against the microtubule-associated protein tau that selectively regulates tau deposits in the brain. Zagotenemab can be used ... | ||||
T76724 | Nemolizumab | 1476039-58-3 | 98% |
Nemolizumab
|
Nemolizumab (CIM331) is a humanized monoclonal antibody against human interleukin-31 receptor A that inhibits the binding and subsequent signal transduction of i... | ||||
T76720 | Farletuzumab | 896723-44-7 | 98% |
Farletuzumab
|
Farletuzumab (MORAb-003) is a potent inhibitor of folate receptor-α (FRα). Farletuzumab is a humanized monoclonal antibody with a high affinity for FRα. Farletuz... | ||||
T76718 | Brentuximab | 2088770-90-3 | 98% |
|
Brentuximab is a chimeric antibody targeting CD30 and is a naked antibody to Brentuximab vedotin.Brentuximab has antitumor activity and may be used to study rela... | ||||
T76717 | Serplulimab | 2231029-82-4 | 98% |
|
Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal... | ||||
T76713 | Inebilizumab | 1299440-37-1 | 98% |
Inebilizumab
|
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used t... | ||||
T76711 | Golimumab | 476181-74-5 | 98% |
|
Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody.Golimumab has anti-inflammatory and anticancer activity, inhibits the production o... | ||||
T76706 | Varlilumab | 1393344-72-3 | 98% |
Varlilumab
|
Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody. Varlilumab has antitumor activity and can be used to study advanced solid tumors. | ||||
T76704 | Tralokinumab | 1044515-88-9 | 98% |
Tralokinumab
|
Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 r... | ||||
T76702 | Sutimlimab | 2049079-64-1 | 98% |
Sutimlimab
|
Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemol... | ||||
T76700 | Simtuzumab | 1318075-13-6 | 98% |
Simtuzumab
|
Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not... | ||||
T76699 | Sabatolimab | 2252262-24-9 | 98% |
Sabatolimab
|
Sabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses. Sab... | ||||
T76698 | Rovalpituzumab | 1613313-01-1 | 98% |
Rovalpituzumab
|
Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used to synthesize antibody-active molecule conjug... | ||||
T76696 | Onvatilimab | 1969313-51-6 | 98% |
Onvatilimab
|
Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody. Onvatilimab has antitumor activity and can ... | ||||
T76692 | Mosunetuzumab | 1905409-39-3 | 98% |
Mosunetuzumab
|
Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to en... | ||||
T76691 | Monalizumab | 1228763-95-8 | 98% |
Monalizumab
|
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NK... | ||||
T76690 | Mavrilimumab | 1085337-57-0 | 98% |
Mavrilimumab
|
Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that has an affinity for the α subunit of the granulocytic-macrophage colony-stimulating... |